99 related articles for article (PubMed ID: 12227070)
21. [Clinical aspects of the complement system].
Tsukamoto H; Horiuchi T
Rinsho Byori; 2006 Jul; 54(7):757-62. PubMed ID: 16913667
[TBL] [Abstract][Full Text] [Related]
22. Complement split products C3a and C4a are early markers of acute lyme disease in tick bite patients in the United States.
Shoemaker RC; Giclas PC; Crowder C; House D; Glovsky MM
Int Arch Allergy Immunol; 2008; 146(3):255-61. PubMed ID: 18270493
[TBL] [Abstract][Full Text] [Related]
23. Changes in plasma levels of complement in patients with acute ischemic stroke.
Cojocaru IM; Cojocaru M; Tănăsescu R; Burcin C; Atanasiu AN; Petrescu AM; Mitu AC; Iliescu I; Dumitrescu L
Rom J Intern Med; 2008; 46(1):77-80. PubMed ID: 19157274
[TBL] [Abstract][Full Text] [Related]
24. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
Wouters D; Brouwer MC; Daha MR; Hack CE
Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
[TBL] [Abstract][Full Text] [Related]
25. Immune complex-like materials in sera of patients with breast cancer: detection by complement-consumption assay.
Sulitzeanu D; Asaf O; Biran S; Brufman G; Gilead Z
Isr J Med Sci; 1981; 17(9-10):869-73. PubMed ID: 7309475
[TBL] [Abstract][Full Text] [Related]
26. Complement activation in patients with primary antiphospholipid syndrome.
Oku K; Atsumi T; Bohgaki M; Amengual O; Kataoka H; Horita T; Yasuda S; Koike T
Ann Rheum Dis; 2009 Jun; 68(6):1030-5. PubMed ID: 18625630
[TBL] [Abstract][Full Text] [Related]
27. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.
Wouters D; Wiessenberg HD; Hart M; Bruins P; Voskuyl A; Daha MR; Hack CE
J Immunol Methods; 2005 Mar; 298(1-2):35-45. PubMed ID: 15847795
[TBL] [Abstract][Full Text] [Related]
28. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer.
Somiari SB; Shriver CD; Heckman C; Olsen C; Hu H; Jordan R; Arciero C; Russell S; Garguilo G; Hooke J; Somiari RI
Cancer Lett; 2006 Feb; 233(1):98-107. PubMed ID: 16473671
[TBL] [Abstract][Full Text] [Related]
29. The functional state of the complement system in leprosy.
Gomes GI; Nahn EP; Santos RK; Da Silva WD; Kipnis TL
Am J Trop Med Hyg; 2008 Apr; 78(4):605-10. PubMed ID: 18385356
[TBL] [Abstract][Full Text] [Related]
30. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
31. Pre-operative levels of serum immunoglobulins, circulating immune complexes and complement proteins in patients with different types of neoplasms.
Gendek-Kubiak H; Grzegorczyk J; Gendek EG; Kowalski ML; Berner J
Arch Immunol Ther Exp (Warsz); 2001; 49 Suppl 2():S89-95. PubMed ID: 11665753
[TBL] [Abstract][Full Text] [Related]
32. [Effects on the amount of total hemolytic complement levels(CH50) and immunoglobulin in serum induced by the implantation of biomaterials into rats].
Zhu M; Zeng Y; Jiang L; Huang P; Wu Z
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 1999 Sep; 16(3):275-8. PubMed ID: 12552743
[TBL] [Abstract][Full Text] [Related]
33. [Serum tumor marker TPS (tissue polypeptide-specific antigen)].
Sergeeva NS; Dubovetskaia OB; Marshutina NV; Rodina IA; Mishunina MP; Beliaeva IG; Nesterova OA; Sergeeva VS
Vopr Onkol; 2004; 50(6):637-43. PubMed ID: 15755055
[No Abstract] [Full Text] [Related]
34. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
35. Correlation between serum thyroxine and complements in patients with multiple sclerosis and neuromyelitis optica.
Zhang B; Jiang Y; Yang Y; Peng F; Hu X
Neuro Endocrinol Lett; 2008 Apr; 29(2):256-60. PubMed ID: 18404143
[TBL] [Abstract][Full Text] [Related]
36. Expression of complement messenger RNAs and proteins by human oligodendroglial cells.
Hosokawa M; Klegeris A; Maguire J; McGeer PL
Glia; 2003 Jun; 42(4):417-23. PubMed ID: 12730962
[TBL] [Abstract][Full Text] [Related]
37. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation.
Dernellis J; Panaretou M
Am J Cardiol; 2006 Jan; 97(2):245-8. PubMed ID: 16442371
[TBL] [Abstract][Full Text] [Related]
38. Classical pathway complement activity in Familial Mediterranean fever.
Mkrtchyan GM; Boyajyan AS; Ayvazyan AA; Beglaryan AA
Clin Biochem; 2006 Jul; 39(7):688-91. PubMed ID: 16631629
[TBL] [Abstract][Full Text] [Related]
39. Studies of monkey complement: measurement of cynomolgus monkey CH50, ACH50, C4, C2 and C3.
Xu H; Kitano E; Sato Y; Kobayashi C; Firdawes S; Kitamura H; Fukuzawa M; Miyagawa S
Xenotransplantation; 2008 Feb; 15(1):14-9. PubMed ID: 18333909
[TBL] [Abstract][Full Text] [Related]
40. Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers.
Zadura AF; Theander E; Blom AM; Trouw LA
Scand J Immunol; 2009 Apr; 69(4):374-80. PubMed ID: 19284503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
